Notably, the combination of losartan (125 μg/mL) and low-dose metformin (2.5 mg/mL) increased the survival of Col4a3−/− Alport syndrome mice more than losartan alone (Fig. 7b). This evidence concerns the gene COL4A3 and Alport syndrome.